NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, News, & Analysis

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) released its earnings results on Monday, November, 26th. The biotechnology company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.06. The biotechnology company earned $67.20 million during the quarter, compared to analysts' expectations of $69.03 million. Enanta Pharmaceuticals had a return on equity of 21.56% and a net margin of 34.82%. The company's quarterly revenue was down 11.5% on a year-over-year basis. During the same period in the prior year, the company earned $1.86 earnings per share. View Enanta Pharmaceuticals' Earnings History.

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 6th 2019. View Earnings Estimates for Enanta Pharmaceuticals.

7 brokers have issued twelve-month price targets for Enanta Pharmaceuticals' stock. Their forecasts range from $80.00 to $133.00. On average, they expect Enanta Pharmaceuticals' stock price to reach $102.60 in the next year. This suggests a possible upside of 35.4% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.

Media stories about ENTA stock have trended negative this week, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Enanta Pharmaceuticals earned a news sentiment score of -2.1 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future.

Some companies that are related to Enanta Pharmaceuticals include Amarin (AMRN), GALAPAGOS NV/S (GLPG), Alkermes (ALKS), United Therapeutics (UTHR), Catalent (CTLT), TESARO (TSRO), FibroGen (FGEN), Amneal Pharmaceuticals (AMRX), GW Pharmaceuticals PLC- (GWPH), Horizon Pharma (HZNP), Array Biopharma (ARRY), Taro Pharmaceutical Industries (TARO), Intercept Pharmaceuticals (ICPT), Emergent Biosolutions (EBS) and Evotec (EVTCY).

Enanta Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Navellier & Associates Inc (0.15%), Louisiana State Employees Retirement System (0.03%) and State of Alaska Department of Revenue (0.03%). Company insiders that own Enanta Pharmaceuticals stock include Jay R Luly, Nathalie Adda, Paul J Mellett and Tim Ocain. View Institutional Ownership Trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Jay R Luly, Nathalie Adda, Paul J Mellett and Tim Ocain. View Insider Buying and Selling for Enanta Pharmaceuticals.

ENTA stock was bought by a variety of institutional investors in the last quarter, including Navellier & Associates Inc and State of Alaska Department of Revenue. View Insider Buying and Selling for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $75.79.

Enanta Pharmaceuticals has a market capitalization of $1.41 billion and generates $206.63 million in revenue each year. The biotechnology company earns $71.95 million in net income (profit) each year or $3.48 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.

The official website for Enanta Pharmaceuticals is http://www.enanta.com.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]